Literature DB >> 32997374

A Call to Action: A Systematic Review Examining the Failure to Include Females and Members of Minoritized Racial/Ethnic Groups in Clinical Trials of Pharmacological Treatments for Alcohol Use Disorder.

Melissa R Schick1, Nichea S Spillane1, Katherine L Hostetler1.   

Abstract

Alcohol use disorder (AUD) presents a significant public health concern given the high prevalence estimates and numerous deleterious-associated consequences. The FDA currently has approved 3 pharmacological treatments for alcohol use disorder: acamprosate, naltrexone, and disulfiram. Previous research suggests that there may exist differences in the prevalence of and outcomes related to AUD across sex and racial/ethnic groups. Other work indicates that there may be differences in the efficacy of existing pharmacological treatments for AUD across demographic groups. The purpose of the present study was to examine the inclusion of women and members of minoritized racial/ethnic groups in published randomized clinical trials of pharmacological treatments for alcohol use disorder since 1994, in accordance with the NIH Revitalization Act of 1993. PubMed was systematically searched using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The initial search located 842 articles. After exclusion of ineligible articles, 102 remained for analysis. Of those included in the review, only 11.8% reported full sex and racial/ethnic characteristics of their study participants. Of the total sample, 6 articles were specifically examining 1 racial/ethnic group, and 11 were specifically examining 1 sex. Two articles (2.2%) did not report information regarding the sex breakdown of their participants, while 47 (49.0%) did not report any information regarding the racial/ethnic breakdown of their sample. Despite guidelines set forth by NIH, only 5.9% of articles conducted subgroup analyses to examine differences in treatment outcomes by sex or race/ethnicity, and only 16.7% of articles included considerations related to cultural inclusion when discussing study limitations. These results varied by medication type. Results suggest that considerably greater efforts must be put forth by the larger scientific community regarding the inclusion, analysis, and reporting of data focused on women and non-White racial and ethnic groups.
© 2020 by the Research Society on Alcoholism.

Entities:  

Keywords:  Acamprosate; Alcohol Use Disorder; Disulfiram; Inclusion; Naltrexone

Year:  2020        PMID: 32997374     DOI: 10.1111/acer.14440

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  5 in total

1.  Drinking to Fit in: The Effects of Drinking Motives and Self-Esteem on Alcohol Use among Female College Students.

Authors:  Melissa R Schick; Tessa Nalven; Nichea S Spillane
Journal:  Subst Use Misuse       Date:  2021-10-22       Impact factor: 2.164

Review 2.  A scoping review of cultural adaptations of substance use disorder treatments across Latinx communities: Guidance for future research and practice.

Authors:  Kamilla L Venner; Alexandra Hernandez-Vallant; Katherine A Hirchak; Jalene L Herron
Journal:  J Subst Abuse Treat       Date:  2022-01-11

3.  Lack of Representation in Psychiatric Research: A Data-Driven Example From Scientific Articles Published in 2019 and 2020 in the American Journal of Psychiatry.

Authors:  Sarah L Pedersen; Rachel Lindstrom; Paula M Powe; Kelly Louie; César Escobar-Viera
Journal:  Am J Psychiatry       Date:  2022-05       Impact factor: 19.242

4.  Sex as a Potential Moderator for Baclofen Response in the Treatment of Alcohol Dependence.

Authors:  Kirsten C Morley; Eva Louie; Tristan Hurzeler; Andrew Baillie; Glenys Dore; Nghi Phung; Paul S Haber
Journal:  Front Glob Womens Health       Date:  2022-03-29

5.  Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.

Authors:  Tessa Nalven; Nichea S Spillane; Melissa R Schick; Lisa L Weyandt
Journal:  Exp Clin Psychopharmacol       Date:  2021-07-05       Impact factor: 3.492

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.